Exonics Therapeutics IPO

Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Cas9 technology which is a potential one-time treatment that would make a permanent correction of the mutation that causes Duchenne by identifying and correcting exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers, enabling patients to improve their lives and have a lifelong benefit.

Register for Details

For more details on financing and valuation for Exonics Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Exonics Therapeutics

Forge green plus iconForge green minus icon

What is Exonics Therapeutics funding to date?

Exonics Therapeutics has raised $45MM to date.
Forge green plus iconForge green minus icon

When was Exonics Therapeutics founded?

Exonics Therapeutics was founded in 2017.
Updated on: Jun 12, 2022